The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …

Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the
second leading cause of cancer-related death affecting men in the United States. Moreover …

Background Next-generation sequencing is revealing genomic heterogeneity in localized
prostate cancer (CaP). Incomplete sampling of CaP multiclonality has limited the …

Prostate cancer (PCa) is one of the most commonly diagnosed human cancers in males.
Nearly 191,930 new cases and 33,330 new deaths of PCa are estimated in 2020. Androgen …

Standard treatment for metastatic prostate cancer (CaP) prevents ligand-activation of
androgen receptor (AR). Despite initial remission, CaP progresses while relying on AR. AR …

Prostate cancer (PCa) is a leading cause of mortality in men of African origin. While men of
African descent in high-income countries (HICs) demonstrate poor prognosis compared to …

Previous studies have demonstrated an involvement of chromatin-remodelling SWI/SNF
complexes in the development of prostate cancer, suggesting both tumor suppressor and …

Patients with localized prostate cancer (PCa) have several therapeutic options with good
prognosis. However, survival of patients with high-risk, advanced PCa is significantly less …

Androgen receptor (AR) is a ligand-activated transcription factor that is the main target for
treatment of non-organ-confined prostate cancer (CaP). Failure of life-prolonging AR …

Simple Summary Prostate cancer cells require androgens to survive and grow. In turn,
targeting androgen signaling has become a predominant therapeutic strategy in this …